Confluent Medical Opens Specialty Medical Polymer Tubing Center of Excellence

Confluent Medical Technologies (“Confluent”) announces today the official opening of their Chattanooga, Tenn., Specialty Polymer Tubing center of excellence.

This new state-of-the-art facility, expected to be operational in Q3 2021, greatly expands Confluent’s ability to provide customers with complex delivery systems for structural heart, neurovascular, and peripheral vascular applications. The capabilities of this new location include PTFE liners, polyimide tubing, multi-layer composite tubing (braided and non-braided), and coated wire.

 

“Having a strong manufacturing location here in the U.S. is vital to supporting our growing customer base,” says Confluent President & CEO Dean Schauer. “Combine this new site’s capabilities with our complex catheter offerings out of our Austin, Texas, site and you have a powerful partner in Confluent Medical to assist with your catheter shaft needs.”

With the addition of filmcast technology, Confluent strengthens its vertically integrated supply chain by offering thin-walled, tightly tolerance engineered tubing. The Chattanooga site, with a technical team having over 175 years of combined experience in medical device manufacturing, will also partner with OEMs to provide customized tubing for demanding devices.

 

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version